Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of novel transmembrane Protease Serine Type 2 drug candidates for COVID-19 using computational studies

1 Jan 2021

Abstract excerpt

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emergence has resulted in a global health crisis. As a consequence, discovering an effective therapy that saves lives and slows the spread of the pandemic is a global concern currently. In silico drug repurposing is highly regarded as a precise computational method for obtaining fast and reliable results. Transmembrane serine-type 2 (TMPRSS2) is a SARS...

Source

Identifiers

PMID: 34514079
DOI: 10.1016/j.imu.2021.100725

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of novel transmembrane Protease Serine Type 2 drug candidates for COVID-19 using computational studiesPMID 34514079Read ↗

Molecular Modeling Targeting Transmembrane Serine Protease 2 (TMPRSS2) as an Alternative Drug Target Against CoronavirusesSemantic proximity Read ↗

In Silico Drug Discovery: The Next Frontier in the Fight Against SARS-CoV-2Semantic proximity Read ↗

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico MethodSemantic proximity Read ↗

Homology Modeling of TMPRSS2 Yields Candidate Drugs That May Inhibit Entry of SARS-CoV-2 into Human CellsSemantic proximity Read ↗

A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19Semantic proximity Read ↗

Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2Semantic proximity Read ↗

Integrated Docking and Enhanced Sampling Based Selection of Repurposing Drugs for SARS-CoV-2 by Targeting Host Dependent FactorsSemantic proximity Read ↗

Old Arsenal to Combat New Enemy: Repurposing of Commercially Available FDA Approved Drugs Against Main Protease of SARS-CoV2.Semantic proximity Read ↗

Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 targetSemantic proximity Read ↗

Identification of promising high-affinity inhibitors of SARS-CoV-2 main protease from African Natural Products Databases by Virtual ScreeningSemantic proximity Read ↗

Identification of SARS‐CoV‐2 Papain‐like Protease (PLpro) Inhibitors Using Combined Computational Approach**Semantic proximity Read ↗

Identification of novel TMPRSS2 inhibitors for COVID-19 using e-pharmacophore modelling, molecular docking, molecular dynamics and quantum mechanics studiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.